Yuankai Shi

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Thales (Australia) · ORCID：0000-0002-8685-6744

发表论文 247 篇 · 总被引 1855 次 · h-index 21

代表论文

• First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 7)
• Multiomics and Single-Cell Insights Reveal a Lysophosphatidic Acid–Mediated Resistant Mechanism to Third-generation EGFR-TKI in Non–Small Cell Lung Cancer (2025 · Clinical Cancer Research · 被引 6)
• Multi-omics unveils BCAA metabolism markers L-leucine and HMGCS1 as prognostic marker for immunotherapy efficacy in non-small cell lung cancer (2025 · Respiratory Research · 被引 6)
• Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study (2025 · BMC Cancer · 被引 4)
• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)
• Establishing the China–UK Cancer Prevention and Control Alliance (2025 · The Lancet Oncology · 被引 1)